SPDYA (Speedy/RINGO Cell Cycle Regulator Family Member A)

Notably, the approach achieved a 92.86% detection rate for stage I endometrial cancer. These results support a robust, noninvasive diagnostic strategy that leverages simple cervical cytology sampling to enable early detection, facilitate clinical decision-making, and potentially improve outcomes for patients at risk of endometrial cancer.

BreastDCEDL fills a critical gap in public imaging resources, supporting development of advanced models for pCR prediction and other breast cancer analyses. The dataset is designed for broad reuse and is accompanied by processing tools to support community-driven AI research in oncology.

Using a conditional mouse model, we demonstrate that driving the expression of Spy1, in the Nestin-enriched NSC population of the brain, increases stemness characteristics, decreases differentiation, and increases susceptibility to oncogenic transformation. This study contributes to better understanding of intricate cell cycle mechanisms that lead to deviation from the homeostatic state, promoting aberrant changes in adult NSCs.

Our study reveals pan-cancer imaging phenotypes that predict survival and provide biological insights, highlighting their potential in precision oncology.

The model constructed based on multiparametric MRI intratumor combined with peritumor radiomics features can better predict luminal and non-luminal types of breast cancer. This study can provide a reference basis for individualized treatment plans for breast cancer.

Our study established a novel noninvasive STI model that integrates the spatiotemporal evolution of MRI before and during NAC to achieve early and accurate pCR prediction, offering potential guidance for personalized treatment. This study was supported by the National Natural Science Foundation of China (82302314, 62271448, 82171920, 81901711), Basic and Applied Basic Research Foundation of Guangdong Province (2022A1515110792, 2023A1515220097, 2024A1515010653), Medical Scientific Research Foundation of Guangdong Province (A2023073, A2024116), Science and Technology Projects in Guangzhou (2023A04J1275, 2024A03J1030, 2025A03J4163, 2025A03J4162); Guangzhou First People's Hospital Frontier Medical Technology Project (QY-C04).

It summarizes first-, second-, and third-generation CDK inhibitors and selective CDK2 inhibitors currently in clinical trials for cancer. Novel strategies to discover allosteric inhibitors, covalent inhibitors, and degraders are also discussed.

P=N/A, N=20, Women's Hospital, School of Medicine, Zhejiang University; Women's Hospital, School of Medicine, Zhejiang University

These findings present potential actionable genomic markers of vincristine neuropathy and offer opportunities for tailored interventions to improve vincristine safety in children with cancer. This study is registered with ClinicalTrials.gov under the title National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children (ID NCT00414115, registered on December 21, 2006).

A nomogram based on these genes was developed. Nevertheless, this study is based on bioinformatics, and experimental validation remains essential.

Moreover, lipid-laden from 127aa positive cancer cells transferred to NK cells inhibited the cytotoxicity. Taken together, circSpdyA encoded 127aa promotes fatty acid de novo synthesis through directly binding with FASN and induced NK cell repression by inhibiting the transcription of NK cell activators.

Regarding the therapeutic implications, the radiomic signature exhibited value when combining clinical factors for predicting the pathological complete response to neoadjuvant chemotherapy (DUKE cohort, AUC = 0.72; I-SPY1 cohort, AUC = 0.73). In conclusion, our study identified a breast cancer outcome-predicting radiomic signature in a multicenter radio-multiomic study, along with its correlations with multiomic features in prognostic risk assessment, laying the groundwork for future prospective clinical trials in personalized risk stratification and precision therapy.